右美托咪定或可乐定镇静与丙泊酚在重症患者中的比较:A2B随机临床试验
A2B随机临床试验在41个ICU纳入1404例机械通气成人,比较右美托咪定或可乐定为基础的镇静与丙泊酚为基础镇静对成功拔管时间的影响。结果显示右美托咪定组与丙泊酚组相比亚分布风险比为1.09(95%CI 0.96-1.25;P=.20),可乐定组与丙泊酚组相比为1.05(95%CI 0.95-1.17;P=.34),两者均未优于丙泊酚。右美托咪定和可乐定组躁动及严重心动过缓发生率高于丙泊酚组。
要点
- 右美托咪定或可乐定镇静相比丙泊酚并未缩短机械通气患者成功拔管时间。
- 右美托咪定组躁动风险比为1.54(95%CI 1.21-1.97),可乐定组为1.55(95%CI 1.22-1.97),均高于丙泊酚组。
- 右美托咪定组严重心动过缓(心率<50次/分)风险比为1.62(95%CI 1.36-1.93),可乐定组为1.58(95%CI 1.33-1.88),均高于丙泊酚组。
核心结论
- 在重症患者中,右美托咪定和可乐定在缩短成功拔管时间方面均未优于丙泊酚。
研究设计与样本
- 实用性、开放标签随机临床试验,在英国41个ICU开展,纳入成人机械通气患者。
- 纳入标准为开始机械通气48小时内、正在使用丙泊酚加阿片类药物镇静镇痛、预计需要机械通气48小时或更长。
- 从插管到随机化的中位时间为21.0(IQR 13.2-31.3)小时。
- 招募时间为2018年12月至2023年10月,末次随访时间为2023年12月10日。
- 分析人群共1404例患者,平均年龄59.2(SD 14.9)岁,901例(64%)为男性,平均APACHE II评分为20.3(SD 8.2)。
主要发现
- 从随机化到成功拔管时间的亚分布风险比:右美托咪定组(n=457)vs丙泊酚组(n=471)为1.09(95%CI 0.96-1.25;P=.20);可乐定组(n=476)vs丙泊酚组(n=471)为1.05(95%CI 0.95-1.17;P=.34)。
- 从随机化到成功拔管的中位时间:右美托咪定组136(95%CI 117-150)小时,可乐定组146(95%CI 124-168)小时,丙泊酚组162(95%CI 136-170)小时。
- 预设亚组分析中,年龄、脓毒症状态、序贯器官衰竭评估评分中位数或谵妄风险评分中位数均无交互作用。
- 与丙泊酚组相比,躁动发生率右美托咪定组风险比为1.54(95%CI 1.21-1.97),可乐定组风险比为1.55(95%CI 1.22-1.97)。
- 与丙泊酚组相比,严重心动过缓(心率<50次/分)发生率右美托咪定组风险比为1.62(95%CI 1.36-1.93),可乐定组风险比为1.58(95%CI 1.33-1.88);180天死亡率右美托咪定组HR为0.98(95%CI 0.77-1.24),可乐定组HR为1.04(95%CI 0.82-1.31)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether α2-adrenergic receptor agonist-based sedation, compared with propofol-based sedation, reduces time to extubation in patients receiving mechanical ventilation in the intensive care unit (ICU) is uncertain. OBJECTIVE: To evaluate whether dexmedetomidine- or clonidine-based sedation reduces duration of mechanical ventilation compared with propofol-based sedation (usual care). DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, open-label randomized clinical trial conducted at 41 ICUs in the UK including adults who were within 48 hours of starting mechanical ventilation, were receiving propofol plus an opioid for sedation and analgesia, and were expected to require mechanical ventilation for 48 hours or longer. The median time from intubation to randomization was 21.0 (IQR, 13.2-31.3) hours. Recruitment occurred from December 2018 to October 2023; the last follow-up occurred on December 10, 2023. INTERVENTIONS: The bedside algorithms used targeted a Richmond Agitation-Sedation Scale score of -2 to 1 (unless clinicians requested deeper sedation). The algorithms supported uptitration in the dexmedetomidine- and clonidine-based sedation intervention groups and supported downtitration for propofol-based sedation followed by sedation primarily with the allocated sedation (dexmedetomidine or clonidine). If required, supplemental use of propofol was permitted. MAIN OUTCOMES AND MEASURES: The primary outcome was time from randomization to successful extubation. The secondary outcomes included mortality, sedation quality, rates of delirium, and cardiovascular adverse events. RESULTS: Among the 1404 patients in the analysis population (mean age, 59.2 [SD, 14.9] years; 901 [64%] were male; and the mean APACHE II score was 20.3 [SD, 8.2]), the subdistribution hazard ratio (HR) for time to successful extubation was 1.09 (95% CI, 0.96-1.25; P = .20) for dexmedetomidine (n = 457) vs propofol (n = 471) and was 1.05 (95% CI, 0.95-1.17; P = .34) for clonidine (n = 476) vs propofol (n = 471). The median time from randomization to successful extubation was 136 (95% CI, 117-150) hours for dexmedetomidine, 146 (95% CI, 124-168) hours for clonidine, and 162 (95% CI, 136-170) hours for propofol. In the predefined subgroup analyses, there were no interactions with age, sepsis status, median Sequential Organ Failure Assessment score, or median delirium risk score. Among the secondary outcomes, agitation occurred at a higher rate with dexmedetomidine vs propofol (risk ratio [RR], 1.54 [95% CI, 1.21-1.97]) and with clonidine vs propofol (RR, 1.55 [95% CI, 1.22-1.97]). Compared with propofol, the rates of severe bradycardia (heart rate <50/min) were higher with dexmedetomidine (RR, 1.62 [95% CI, 1.36-1.93]) and clonidine (RR, 1.58 [95% CI, 1.33-1.88]). Compared with propofol, mortality was similar over 180 days for dexmedetomidine (HR, 0.98 [95% CI, 0.77-1.24]) and clonidine (HR, 1.04 [95% CI, 0.82-1.31]). CONCLUSIONS AND RELEVANCE: In critically ill patients, neither dexmedetomidine nor clonidine was superior to propofol in reducing time to successful extubation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03653832.
引用
- Walsh TS, Parker RA, Aitken LM, et al. Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial. JAMA. 2025. PMID: 40388916. doi:10.1001/jama.2025.7200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。